Share Issue/Capital Change • Aug 25, 2015
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
News Details
Corporate | 25 August 2015 09:57
STRATEC converts to registered shares
STRATEC Biomedical AG / Key word(s): Miscellaneous
2015-08-25 / 09:57
STRATEC converts to registered shares
Birkenfeld, August 25, 2015
STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX) is converting its share capital, currently comprising 11,846,595 shares, after the close of trading on Friday, August 28, 2015, at a ratio of 1:1 from bearer shares with a nominal amount of EUR 1.00 to registered shares in the form of no-par shares (shares without a nominal amount). Shareholdings will be converted by custodian banks and at no charge to shareholders.
This conversion to registered shares, which was approved by the Annual General Meeting on May 22, 2015, is meant to facilitate direct communication with shareholders and increase transparency of the shareholder structure.
All shares in STRATEC Biomedical AG will be listed in the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) as registered shares for the first time on Monday, August 31, 2015. From this point onwards, only the new international and German security identification numbers will be valid, namely ISIN DE000STRA555 (to date DE000728900) and WKN STRA55 (to date 728900). The company’s ticker symbol SBS will remain unchanged.
Further information about this conversion to registered shares can be found at www.stratec.com/registered_shares .
About STRATEC
STRATEC Biomedical AG ( www.stratec.com ) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
2015-08-25 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | STRATEC Biomedical AG |
| Gewerbestr. 37 | |
| 75217 Birkenfeld | |
| Germany | |
| Phone: | +49 (0)7082 7916 0 |
| Fax: | +49 (0)7082 7916 999 |
| E-mail: | [email protected] |
| Internet: | www.stratec.com |
| ISIN: | DE0007289001 |
| WKN: | 728900 |
| Indices: | TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart |
| End of News | DGAP News-Service |
| - - - |
| 388993 2015-08-25 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.